Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

Despite the setback with HexaBody-CD38, William Blair upgraded Genmab’s stock rating from Market Perform to Outperform, citing the company’s promising pipeline, including treatments like ...

Despite the setback with HexaBody-CD38, William Blair upgraded Genmab’s stock rating from Market Perform to Outperform, citing the company’s promising pipeline, including treatments like Epkinly and ...

GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...

William Blair analyst Andy Hsieh reiterated a Hold rating on FibroGen (FGEN – Research Report) today. The company’s shares closed yesterday at ...

Shares of Genmab A/S (GMAB) fell this week after partner Johnson & Johnson (JNJ) unsurprisingly opted out of the deal to develop and commercialize GEN3014, Genmab’s next-generation CD38 HexaBody ...

At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management and the year's ...